Project Grant R03CA303738
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $544,250 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Nebraska Medical Center (UNMC) will support research to investigate the immune drivers of persistent oncogenic infections, such as oral human papillomavirus (HPV), and their progression to cancer among people living with HIV. The overarching goal is to improve prevention, early detection, and treatment outcomes for infection-related cancers in this high-risk...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...
- The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, awarded a $660,205 Project Grant to The University of Texas Southwestern Medical Center to develop small molecule inhibitors targeting the bromodomain-containing protein 4 (BRD4) to block human papillomavirus (HPV) genome replication. The grant aims to identify and characterize compounds that can effectively inhibit the three stages of HPV DNA replication by targeting the phosphorylated...
- The University of Texas Medical Branch at Galveston (UTMB) was awarded a $811,033 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the "HPV and Risk to Pregnancy (HARP)" study. This prospective cohort study of 1,280 pregnancies aims to determine if vaginal high-risk human papillomavirus (HPV) infection at 20 weeks gestation, or persistent or new infection in the third...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $6,319,992 to Tufts University School of Medicine to conduct research on how human papillomavirus (HPV) proteins reprogram host cell signaling pathways. The research aims to determine the essential cellular targets of the HPV E7 protein, specifically the RB1 and PTPN14 tumor suppressors, and how their inactivation enables HPV to drive...
- The University of North Carolina at Chapel Hill (UNC-CH) was awarded a $688,458 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a pilot Phase IIA randomized placebo-controlled trial evaluating the safety, adherence, and preliminary efficacy of using 5-fluorouracil (5FU) as an adjuvant intravaginal therapy following thermal ablation to improve human papillomavirus (HPV) treatment outcomes in women living with...
- The National Cancer Institute (NCI), through the Cancer Research Manpower (CFDA 93.398) federal grant program, awarded Northwestern University a $191,700 Project Grant to develop and test a culturally-relevant digital health intervention targeting HPV vaccination among U.S. Vietnamese individuals. The project, titled "Applying the Multiphase Optimization Strategy to Develop and Test a Culturally-Relevant Digital Health Intervention Targeting HPV Vaccination Among U.S. Vietnamese", will...
- This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...
- This $495,374.00 Project Grant was awarded by the National Cancer Institute, part of the National Institutes of Health, under the Cancer Biology Research federal grant program (CFDA 93.396). The grant supports research at Northwestern University to investigate the role of R-loops, which are trimeric nucleic acid structures, in the life cycle of human papillomaviruses (HPVs) and their impact on viral replication and transcription. The research aims to advance scientific understanding of how HPV...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $233,411 to Pennsylvania State University's Milton S. Hershey Medical Center to conduct a randomized controlled trial (RCT) evaluating a narrative communication intervention delivered through digital and mobile technology. The goal is to understand how narrative messaging can influence HPV vaccine decision-making and increase HPV vaccine initiation rates among parents of...